Oliver Reuss
Executive Director and Investment Manager @ Boehringer Ingelheim Venture Fund
Oliver Reuss is a Series A investor at Boehringer Ingelheim Venture Fund focused on Medical and Software. Oliver Reuss serves as an Executive Director and Investment Manager at Boehringer Ingelheim Venture Fund.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Oliver Reuss invests in
Stages Oliver Reuss invests in
Countries Oliver Reuss invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (33%)
- Software 1 (33%)
- Wellness 1 (33%)
- Therapeutics 1 (33%)
- Biotechnology 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
- Series C 1 (33%)
Country
- Germany 1 (33%)
- United Kingdom 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $18.2M / Series C / Mar 18, 2025 | ||
| Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $21.3M / Series B / Dec 16, 2021 | ||
| Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects. | $6M / Series A / Nov 30, 2020 |
Co-Investors
Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.
Boehringer Ingelheim Venture Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Debbie Lin
Executive Director
|
|||
Martin Heidecker
Managing Director
|
|||
Knut Elbers
Project Manager
|
|||
|
Oliver Reuss
Executive Director and Investment Manager
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Oliver Reuss invest in?
Oliver Reuss invests primarily in Medical, Software and Wellness startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Oliver Reuss?
Public channels for Oliver Reuss include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Oliver Reuss last invest?
The most recent investment recorded for Oliver Reuss closed in Mar 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
